Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT01254773 | Amyloid Imaging And Safety Study Of Subcutaneous Bapineuzumab In Subjects With Mild to Moderate Alzheimer's Disease | PHASE2 | COMPLETED | 146 | — | — | Dec 1, 2010 | Mar 1, 2013 | May 9, 2014 | 28 | United States |
| Arm | Type | Description |
|---|---|---|
| Bapineuzumab SC Dose 1; 2 mg | EXPERIMENTAL | - |
| Bapineuzumab SC Dose 2; 7 mg | EXPERIMENTAL | - |
| Bapineuzumab SC Dose 3; 20 mg | EXPERIMENTAL | - |
| Placebo | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| Experimental Bapineuzumab | DRUG | Bapineuzumab 2 mg, Bapineuzumab 7 mg, Bapineuzumab 20 mg, Placebo |
Inclusion Criteria: * Diagnosis of probable AD * Age from 50 to less than 89 * Mini-Mental Status Exam score of 18-26 inclusive * Brain magnetic resonance imaging (MRI) scan consistent with the diagnosis of AD * Stable doses of medications (cholinesterase inhibitors and memantine allowed) * Caregiv...